ArticleCancer management and research2022

Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors.

Priyanka Gaitonde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.